Adamax / ADA MAX

Adamax from Super Human Peptides UK is a highly advanced, synthetic nootropic peptide. It is the ultimate structural evolution of the famous Russian neuro-peptide Semax (an ACTH analogue), engineered specifically for maximum stability and extreme central nervous system penetration. In laboratory research, standard Semax is highly effective but vulnerable to rapid enzymatic degradation.

Adamax solves this by attaching an adamantane group to the N-terminus of the peptide chain. This highly lipophilic (fat-soluble) adamantyl modification physically shields the peptide from blood enzymes and acts as a molecular "battering ram," allowing it to effortlessly cross the blood-brain barrier (BBB). Once inside the brain, researchers utilize Adamax to trigger a massive, sustained up-regulation of Brain-Derived Neurotrophic Factor (BDNF) and activate the TrkB receptor pathways.

Produced under GMP-compliant conditions and verified for 99% purity or higher, Adamax is the premier preclinical model for investigating extreme cognitive enhancement, neuro-protection, and rapid recovery from traumatic brain injury (TBI).

• —Adamantane Bioconjugation: Features a lipophilic adamantyl group that drastically increases stability and ensures near-total blood-brain barrier penetration.
• —Semax Evolution: The most potent known derivative of the original MEHFPGP (Semax) sequence, massively outperforming baseline ACTH analogues.
• —BDNF / TrkB Amplification: Triggers profound expression of Brain-Derived Neurotrophic Factor to stimulate the physical growth and survival of new neurons.
• —Cognitive Architecture: Heavily studied for its ability to improve spatial memory, learning acquisition, and extreme mental endurance in compromised models.
• —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
• —Quality Standard: GMP / ISO certified manufacturing.

• —Blood-Brain Barrier Kinetics: Studying the extreme lipophilicity granted by the adamantyl group, mapping how rapidly and efficiently the peptide enters central nervous tissue.
• —BDNF Expression: Measuring the dose-dependent surge of Brain-Derived Neurotrophic Factor in the hippocampus and cerebral cortex following administration.
• —Cognitive Endurance Modeling: Preclinical evaluation of the peptide's ability to maintain focus, learning acquisition, and memory consolidation in animal models subjected to severe sleep deprivation or chronic stress.
• —Hypoxia and Ischemic Protection: Investigating the rapid salvage of neurons and the prevention of cellular apoptosis following restricted oxygen or blood flow to the brain.
• —Synaptic Plasticity: Evaluating the strengthening of neural circuits and the physical outgrowth of dendritic spines driven by TrkB receptor activation.

The development of Adamax represents the absolute pinnacle of Russian neuro-peptide engineering. The foundational peptide, Semax, was heavily utilized for stroke recovery and cognitive enhancement but was limited by its biological half-life. Researchers realized that by applying the "adamantane modification"—a technique previously used to create the neurogenic peptide P21 from Cerebrolysin—they could solve the stability issue.

In advanced laboratory modeling, the addition of the adamantane group to the Semax sequence yielded spectacular results. Preclinical assays demonstrate that Adamax is exponentially more potent than baseline Semax or even N-Acetyl Semax Amidate. Because the adamantane group prevents the peptide from breaking down in the bloodstream and forces it directly into the brain, it triggers a massive and sustained release of BDNF.

Because it physically restructures the brain for optimal performance and survival, it is considered one of the most powerful neuro-regenerative tools in modern nootropic research.

• 1.Dolotov, O.V. et al., "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus," Brain Research, 2006. (Contextual foundation for Semax BDNF pathways).
• 2.Asmarn, O. et al., "Adamantane derivatives: A new class of potent neuroprotectants," European Journal of Medicinal Chemistry. (Contextual data on adamantyl BBB penetration).
• 3.Kaplan, A.Y. et al., "Synthetic ACTH analogue Semax displays nootropic-like activity in humans," Neuroscience Research Communications, 1996.
• 4.Dmitrieva, V.G. et al., "Semax and MEHFPGP affect the expression of genes related to the immune and nervous systems in rat brain focal ischemia," Molecular Genetics and Genomics, 2010.